MCID: SQM002
MIFTS: 42

Squamous Cell Papilloma

Categories: Cancer diseases, Oral diseases, Skin diseases

Aliases & Classifications for Squamous Cell Papilloma

MalaCards integrated aliases for Squamous Cell Papilloma:

Name: Squamous Cell Papilloma 12 15
Papilloma 43 71
Papilloma, Squamous Cell 71
Epidermoid Papilloma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:139
MeSH 43 D010212
NCIt 49 C3712
SNOMED-CT 67 63451008
UMLS 71 C0030354 C0205874

Summaries for Squamous Cell Papilloma

MalaCards based summary : Squamous Cell Papilloma, also known as papilloma, is related to skin papilloma and papillary adenoma. An important gene associated with Squamous Cell Papilloma is SNORD102 (Small Nucleolar RNA, C/D Box 102), and among its related pathways/superpathways is Viral carcinogenesis. The drugs Bethanechol and Cidofovir have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and cervix.

Wikipedia : 74 A squamous cell papilloma is a generally benign papilloma that arises from the stratified squamous... more...

Related Diseases for Squamous Cell Papilloma

Diseases related to Squamous Cell Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 813)
# Related Disease Score Top Affiliating Genes
1 skin papilloma 33.4 TP53 KRT14 HRAS
2 papillary adenoma 32.8 TP53 HRAS
3 in situ carcinoma 30.9 TP53 KRT14 HRAS
4 anus cancer 30.7 TP53 HRAS
5 basaloid squamous cell carcinoma 30.3 TP53 KRT14
6 oropharynx cancer 30.0 TP53 KRT14 HRAS
7 sebaceous adenocarcinoma 29.8 TP53 KRT14
8 comedo carcinoma 29.7 TP53 KRT14
9 large cell acanthoma 29.7 TP53 KRT14
10 tonsil cancer 29.7 TP53 KRT14
11 sweat gland neoplasm 29.7 TP53 KRT14
12 lung adenoma 29.4 TP53 HRAS
13 skin squamous cell carcinoma 29.4 TP53 KRT14 HRAS
14 pleomorphic adenoma 29.4 TP53 KRT14 HRAS
15 suppression of tumorigenicity 12 29.3 TP53 KRT14 HRAS
16 papilloma of choroid plexus 12.8
17 intraductal papilloma 12.5
18 esophagus squamous cell papilloma 12.5
19 squamous cell papilloma of skin 12.4
20 central breast papilloma 12.4
21 bladder transitional cell papilloma 12.4
22 sclerosing breast papilloma 12.3
23 atypical breast papilloma 12.3
24 breast duct papilloma 12.3
25 transitional papilloma 12.3
26 atypical choroid plexus papilloma 12.3
27 maxillary sinus inverted papilloma 12.3
28 ureter inverted papilloma 12.3
29 frontal sinus inverted papilloma 12.3
30 inverted transitional papilloma 12.3
31 nasal vestibule papilloma 12.3
32 sphenoid sinus inverted papilloma 12.3
33 urinary bladder inverted papilloma 12.2
34 vulvar squamous papilloma 12.2
35 urethra inverted papilloma 12.2
36 serous surface papilloma 12.2
37 renal pelvis inverted papilloma 12.2
38 ethmoid sinus inverted papilloma 12.2
39 maxillary sinus schneiderian papilloma 12.2
40 cervix squamous papilloma 12.2
41 fallopian tube serous papilloma 12.2
42 nasal cavity inverting papilloma 12.2
43 vaginal mullerian papilloma 12.1
44 vaginal squamous papilloma 12.1
45 verrucous papilloma 12.1
46 frontal sinus schneiderian papilloma 12.1
47 ethmoid sinus schneiderian papilloma 12.1
48 ureter urothelial papilloma 12.1
49 sphenoid sinus schneiderian papilloma 12.1
50 cervical mullerian papilloma 12.1

Graphical network of the top 20 diseases related to Squamous Cell Papilloma:



Diseases related to Squamous Cell Papilloma

Symptoms & Phenotypes for Squamous Cell Papilloma

Drugs & Therapeutics for Squamous Cell Papilloma

Drugs for Squamous Cell Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 278)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bethanechol Approved Phase 4 674-38-4 2370
2
Cidofovir Approved Phase 4 113852-37-2 60613
3
Polihexanide Approved, Investigational Phase 4 28757-47-3
4
Cantharidin Approved, Investigational Phase 4 56-25-7
5
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
6
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
7
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
8
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
9
Dolutegravir Approved Phase 4 1051375-16-6 54726191
10
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
11
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
12 Muscarinic Agonists Phase 4
13 Hypoglycemic Agents Phase 4
14 Chlorhexidine gluconate Phase 4
15 Biguanides Phase 4
16 Disinfectants Phase 4
17 Anti-Infective Agents, Local Phase 4
18 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
19 MF59 oil emulsion Phase 4
20 HIV Protease Inhibitors Phase 4
21
protease inhibitors Phase 4
22 Vaccines Phase 4
23 Anti-Infective Agents Phase 4
24 Anti-Retroviral Agents Phase 4
25 Antiviral Agents Phase 4
26 Anti-HIV Agents Phase 4
27 Cytochrome P-450 Enzyme Inhibitors Phase 4
28 Antibiotics, Antitubercular Phase 4
29 Anti-Bacterial Agents Phase 4
30 insulin Phase 4
31 Insulin, Globin Zinc Phase 4
32 Cytochrome P-450 CYP3A Inhibitors Phase 4
33 HIV Integrase Inhibitors Phase 4
34 Integrase Inhibitors Phase 4
35
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
36
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
37
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
38
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
39
Histamine Approved, Investigational Phase 3 51-45-6 774
40
Azithromycin Approved Phase 3 83905-01-5 55185 447043
41
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
42
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
43
Promethazine Approved, Investigational Phase 3 60-87-7 4927
44
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
46
Zinc Approved, Investigational Phase 3 7440-66-6 32051
47
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
48
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
49
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3

Interventional clinical trials:

(show top 50) (show all 475)
# Name Status NCT ID Phase Drugs
1 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Unknown status NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
2 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
3 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Unknown status NCT01101750 Phase 4
4 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
5 A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines Completed NCT00956553 Phase 4
6 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
7 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
8 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
9 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
10 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
11 Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination Completed NCT02225327 Phase 4
12 Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
13 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
14 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
15 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
16 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Recruiting NCT03391921 Phase 4
17 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
18 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
19 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
20 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
21 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
22 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
23 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
24 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
25 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
26 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
27 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
28 An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea Completed NCT00157950 Phase 3
29 Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India Completed NCT00380367 Phase 3
30 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
31 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
32 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
33 A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls Completed NCT01254643 Phase 3
34 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
35 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
36 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
37 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
38 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
39 A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
40 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
41 A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study). Completed NCT00092547 Phase 3
42 Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process Completed NCT00169494 Phase 3
43 Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years) Completed NCT00196924 Phase 3
44 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
45 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
46 A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age. Completed NCT00122681 Phase 3
47 Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Completed NCT00090220 Phase 3
48 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
49 A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
50 A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults Completed NCT01164722 Phase 3

Search NIH Clinical Center for Squamous Cell Papilloma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


podophyllin
PODOPHYLLIN PWDR

Cochrane evidence based reviews: papilloma

Genetic Tests for Squamous Cell Papilloma

Anatomical Context for Squamous Cell Papilloma

MalaCards organs/tissues related to Squamous Cell Papilloma:

40
Breast, Skin, Cervix, Testes, T Cells, Lung, Brain

Publications for Squamous Cell Papilloma

Articles related to Squamous Cell Papilloma:

(show top 50) (show all 13741)
# Title Authors PMID Year
1
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
2
Transcriptionally Active HPV and Targetable EGFR Mutations in Sinonasal Inverted Papilloma: An Association Between Low-risk HPV, Condylomatous Morphology, and Cancer Risk? 61
31743131 2020
3
An update on systemic therapy for penile cancer. 61
31972637 2020
4
Intraductal sebaceous papilloma of a meibomian gland: a new entity possibly associated with the MSH6 subtype of the Muir-Torre syndrome. 61
31557488 2020
5
Strengthening health care worker engagement with early adolescence in low- and middle-income countries: an overdue area for action. 61
32031974 2020
6
A proposal for classification of oropharyngeal squamous cell carcinoma: Morphology and status of HPV by immunohistochemistry and molecular biology. 61
31465605 2020
7
Histopathological evaluation of minor salivary gland papillary-cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. 61
31505033 2020
8
Assessing oral cancer awareness among dental and medical students of a Malaysian private university. 61
31691268 2020
9
Multi-Year Effect of Human Papillomavirus Vaccination on Recurrent Respiratory Papillomatosis. 61
30963598 2020
10
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. 61
31785230 2020
11
Single nucleotide polymorphisms in transcription factor genes associated with susceptibility to oral cancer. 61
31452252 2020
12
Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer. 61
31340702 2020
13
Health system factors influencing uptake of Human Papilloma Virus (HPV) vaccine among adolescent girls 9-15 years in Mbale District, Uganda. 61
32019543 2020
14
Sudden appearance of widespread esophageal squamous papilloma with reflux esophagitis. 61
32036041 2020
15
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). 61
31851776 2020
16
Anal squamous intraepithelial lesions: an update and proposed management algorithm. 61
31834554 2020
17
Identifying patterns of failure and secondary primary malignancies in HPV-related oropharyngeal squamous cell carcinomas. 61
31967480 2020
18
Prognostic significance of MTOR expression in HPV positive and negative head and neck cancers treated by chemoradiation. 61
31657099 2020
19
Membrane partitioning of peptide aggregates: coarse-grained molecular dynamics simulations. 61
30774024 2020
20
Assessment and management of B3 breast lesions with atypia: a focused review. 61
31566023 2020
21
Impact of clinical complete response on treatment outcomes in patients with locally advanced HPV-negative oropharyngeal squamous cell carcinoma. 61
31686249 2020
22
The landscape of viral associations in human cancers. 61
32025001 2020
23
Application of deep learning to the classification of uterine cervical squamous epithelial lesion from colposcopy images combined with HPV types. 61
31966086 2020
24
Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease-a 16-year follow-up study. 61
31473226 2020
25
Villitis of unknown etiology and chronic deciduitis are not associated with human papilloma virus and enterovirus infection. 61
32025822 2020
26
Human papilloma virus related squamous cell carcinomas of the head and neck: diagnosis, clinical implications and detection of HPV. 61
31889547 2020
27
Inverted papilloma is associated with greater radiographic inflammatory disease than other sinonasal malignancy. 61
32022422 2020
28
Discovering pH triggered charge rebound surface modulated topical nanotherapy against aggressive skin papilloma. 61
31761163 2020
29
Improvement in RNA quantity and quality in cervico-vaginal cytology. 61
31959186 2020
30
Impact of HPV Immunization Training on Dental Hygiene Students' Attitudes and Confidence Regarding HPV Preventive Education. 61
31977100 2020
31
Men having sex with men and the HPV vaccine in France: A low vaccine coverage that may be due to its infrequent proposal by physicians. 61
32008880 2020
32
Role of human papillomavirus in laryngeal squamous cell carcinoma: A meta-analysis of cohort study. 61
31733044 2020
33
Human Papillomavirus and Factors Associated with Recurrence in Sinonasal Inverted Papillomas from Poland and Spain. 61
31916205 2020
34
The incidence of oropharyngeal cancer and rate of human papillomavirus vaccination coverage in Florida, 2011 through 2015. 61
31902400 2020
35
p16 Positive Histologically Bland Squamous Metaplasia of the Cervix: What does It Signify? 61
31498174 2020
36
Awareness and knowledge of human papilloma virus in UK women aged 25 years and over: Results from a cross-sectional internet-based survey. 61
31639253 2020
37
A Rare Instance of Primary Oncocytic Schneiderian Papilloma of Middle Ear and Eustachian Tube With a Combined Trans Oto and Nasal Approach Resection. 61
31977707 2020
38
Simultaneous Resection of Pituitary Macroadenoma and Sphenoid Sinus Inverted Papilloma: The Challenge of Operating Sinonasal and Skull Base Pathologies Through a Single-Stage Endoscopic Endonasal Approach. 61
31605847 2020
39
Letter to the Editor: Authors' response to letter to the Editor: Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. 61
31788949 2020
40
Authors' response to letter to the editor, letter to the editor: Authors' response to letter to the editor: Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. 61
31788952 2020
41
Virus-like particles for vaccination against cancer. 61
31456339 2020
42
Prevalence of Human Papilloma Virus in Oman; Genotypes 82, 68, 56 and 53 are dominating. 61
31935539 2020
43
Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. 61
31566705 2020
44
Anti-HPV Nanoemulsified-Imiquimod: A New and Potent Formulation to Treat Cervical Cancer. 61
31907712 2020
45
Suppression of HIF-1α accumulation by betulinic acid through proteasome activation in hypoxic cervical cancer. 61
31948750 2020
46
SEOM clinical guidelines for cervical cancer (2019). 61
31981078 2020
47
Prevalence of human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer in imprisoned women worldwide: a systematic review and meta-analysis. 61
31649041 2020
48
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. 61
31413005 2020
49
Vaccination Programs for Adults in Europe, 2019. 61
31968652 2020
50
Yaws in the Philippines: first reported cases since the 1970s. 61
31996251 2020

Variations for Squamous Cell Papilloma

Cosmic variations for Squamous Cell Papilloma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM138041675 upper aerodigestive tract,larynx,other,papilloma c.140A>G p.H47R 9:21971066-21971066 0

Expression for Squamous Cell Papilloma

Search GEO for disease gene expression data for Squamous Cell Papilloma.

Pathways for Squamous Cell Papilloma

Pathways related to Squamous Cell Papilloma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.1 TP53 HRAS H2BC1

GO Terms for Squamous Cell Papilloma

Biological processes related to Squamous Cell Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intrinsic apoptotic signaling pathway GO:0097193 9.16 TP53 HRAS
2 cellular response to gamma radiation GO:0071480 8.96 TP53 HRAS
3 cell aging GO:0007569 8.62 TP53 HRAS

Sources for Squamous Cell Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....